A gene therapy for cancer based on the angiogenesis inhibitor, vasostatin

F. Xiao, Y. Wei, L. Yang, X. Zhao, L. Tian, Z. Ding, S. Yuan, Yanyan Lou, F. Liu, Y. Wen, J. Li, H. Deng, B. Kang, Y. Mao, S. Lei, Q. He, J. Su, Y. Lu, T. Niu, J. HouM. J. Huang

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

The growth and persistence of solid tumors and their metastasis are angiogenesis-dependent. Vasostatin, the N-terminal domain of calreticulin inclusive of amino acids 1-180, is a potent angiogenesis inhibitor. To investigate whether intramuscular administration of vasostatin gene has the anti-tumor activity in mouse tumor models, we constructed a plasmid DNA encoding vasostatin and a control vector. Production and secretion of vasostatin protein by COS cells transfected with the plasmid DNA encoding vasostatin (pSecTag2B-vaso) were confirmed by Western blot analysis and ELISA. Conditioned medium from vasostatin-transfected COS cells apparently inhibited human umbilical vein endothelial cell (HUVEC) and mouse endothelial cell (SVEC4-10) proliferation, compared with conditioned medium from the COS cells transfected with control vector or non-transfected cells. Treatment with pSecTag2B-vaso twice weekly for 4 weeks resulted in the inhibition of tumor growth and the prolongation of the survival of tumor-bearing mice. The sustained high level of vasostatin protein in serum could be identified in ELISA. Angiogenesis was apparently inhibited in tumor by immunohistochemical analysis. Angiogenesis was also inhibited in the chicken embryo CAM assay and mouse corneal micropocket assay. The increased apoptotic cells were found within the tumor tissues from the mice treated with plasmid DNA encoding vasostatin. Taken together, the data in the present study indicate that the cancer gene therapy by the intramuscular delivery of plasmid DNA encoding vasostatin, is effective in the inhibition of the systemic angiogenesis and tumor growth in murine models. The present findings also provide further evidence of the anti-tumor effects of the vasostatin, and may be of importance for the further exploration of the application of this molecule in the treatment of cancer.

Original languageEnglish (US)
Pages (from-to)1207-1213
Number of pages7
JournalGene Therapy
Volume9
Issue number18
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Angiogenesis Inhibitors
Genetic Therapy
Neoplasms
COS Cells
Plasmids
DNA
Conditioned Culture Medium
Growth
Enzyme-Linked Immunosorbent Assay
vasostatin
Calreticulin
Neoplasm Genes
Human Umbilical Vein Endothelial Cells
Blood Proteins
Chickens
Embryonic Structures
Endothelial Cells
Western Blotting
Neoplasm Metastasis
Amino Acids

Keywords

  • Angiogenesis
  • Dna plasmid
  • Gene therapy
  • Vasostatin

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Xiao, F., Wei, Y., Yang, L., Zhao, X., Tian, L., Ding, Z., ... Huang, M. J. (2002). A gene therapy for cancer based on the angiogenesis inhibitor, vasostatin. Gene Therapy, 9(18), 1207-1213. https://doi.org/10.1038/sj.gt.3301788

A gene therapy for cancer based on the angiogenesis inhibitor, vasostatin. / Xiao, F.; Wei, Y.; Yang, L.; Zhao, X.; Tian, L.; Ding, Z.; Yuan, S.; Lou, Yanyan; Liu, F.; Wen, Y.; Li, J.; Deng, H.; Kang, B.; Mao, Y.; Lei, S.; He, Q.; Su, J.; Lu, Y.; Niu, T.; Hou, J.; Huang, M. J.

In: Gene Therapy, Vol. 9, No. 18, 2002, p. 1207-1213.

Research output: Contribution to journalArticle

Xiao, F, Wei, Y, Yang, L, Zhao, X, Tian, L, Ding, Z, Yuan, S, Lou, Y, Liu, F, Wen, Y, Li, J, Deng, H, Kang, B, Mao, Y, Lei, S, He, Q, Su, J, Lu, Y, Niu, T, Hou, J & Huang, MJ 2002, 'A gene therapy for cancer based on the angiogenesis inhibitor, vasostatin', Gene Therapy, vol. 9, no. 18, pp. 1207-1213. https://doi.org/10.1038/sj.gt.3301788
Xiao, F. ; Wei, Y. ; Yang, L. ; Zhao, X. ; Tian, L. ; Ding, Z. ; Yuan, S. ; Lou, Yanyan ; Liu, F. ; Wen, Y. ; Li, J. ; Deng, H. ; Kang, B. ; Mao, Y. ; Lei, S. ; He, Q. ; Su, J. ; Lu, Y. ; Niu, T. ; Hou, J. ; Huang, M. J. / A gene therapy for cancer based on the angiogenesis inhibitor, vasostatin. In: Gene Therapy. 2002 ; Vol. 9, No. 18. pp. 1207-1213.
@article{5e06aee06c774338bd4f4885fa64a9de,
title = "A gene therapy for cancer based on the angiogenesis inhibitor, vasostatin",
abstract = "The growth and persistence of solid tumors and their metastasis are angiogenesis-dependent. Vasostatin, the N-terminal domain of calreticulin inclusive of amino acids 1-180, is a potent angiogenesis inhibitor. To investigate whether intramuscular administration of vasostatin gene has the anti-tumor activity in mouse tumor models, we constructed a plasmid DNA encoding vasostatin and a control vector. Production and secretion of vasostatin protein by COS cells transfected with the plasmid DNA encoding vasostatin (pSecTag2B-vaso) were confirmed by Western blot analysis and ELISA. Conditioned medium from vasostatin-transfected COS cells apparently inhibited human umbilical vein endothelial cell (HUVEC) and mouse endothelial cell (SVEC4-10) proliferation, compared with conditioned medium from the COS cells transfected with control vector or non-transfected cells. Treatment with pSecTag2B-vaso twice weekly for 4 weeks resulted in the inhibition of tumor growth and the prolongation of the survival of tumor-bearing mice. The sustained high level of vasostatin protein in serum could be identified in ELISA. Angiogenesis was apparently inhibited in tumor by immunohistochemical analysis. Angiogenesis was also inhibited in the chicken embryo CAM assay and mouse corneal micropocket assay. The increased apoptotic cells were found within the tumor tissues from the mice treated with plasmid DNA encoding vasostatin. Taken together, the data in the present study indicate that the cancer gene therapy by the intramuscular delivery of plasmid DNA encoding vasostatin, is effective in the inhibition of the systemic angiogenesis and tumor growth in murine models. The present findings also provide further evidence of the anti-tumor effects of the vasostatin, and may be of importance for the further exploration of the application of this molecule in the treatment of cancer.",
keywords = "Angiogenesis, Dna plasmid, Gene therapy, Vasostatin",
author = "F. Xiao and Y. Wei and L. Yang and X. Zhao and L. Tian and Z. Ding and S. Yuan and Yanyan Lou and F. Liu and Y. Wen and J. Li and H. Deng and B. Kang and Y. Mao and S. Lei and Q. He and J. Su and Y. Lu and T. Niu and J. Hou and Huang, {M. J.}",
year = "2002",
doi = "10.1038/sj.gt.3301788",
language = "English (US)",
volume = "9",
pages = "1207--1213",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "18",

}

TY - JOUR

T1 - A gene therapy for cancer based on the angiogenesis inhibitor, vasostatin

AU - Xiao, F.

AU - Wei, Y.

AU - Yang, L.

AU - Zhao, X.

AU - Tian, L.

AU - Ding, Z.

AU - Yuan, S.

AU - Lou, Yanyan

AU - Liu, F.

AU - Wen, Y.

AU - Li, J.

AU - Deng, H.

AU - Kang, B.

AU - Mao, Y.

AU - Lei, S.

AU - He, Q.

AU - Su, J.

AU - Lu, Y.

AU - Niu, T.

AU - Hou, J.

AU - Huang, M. J.

PY - 2002

Y1 - 2002

N2 - The growth and persistence of solid tumors and their metastasis are angiogenesis-dependent. Vasostatin, the N-terminal domain of calreticulin inclusive of amino acids 1-180, is a potent angiogenesis inhibitor. To investigate whether intramuscular administration of vasostatin gene has the anti-tumor activity in mouse tumor models, we constructed a plasmid DNA encoding vasostatin and a control vector. Production and secretion of vasostatin protein by COS cells transfected with the plasmid DNA encoding vasostatin (pSecTag2B-vaso) were confirmed by Western blot analysis and ELISA. Conditioned medium from vasostatin-transfected COS cells apparently inhibited human umbilical vein endothelial cell (HUVEC) and mouse endothelial cell (SVEC4-10) proliferation, compared with conditioned medium from the COS cells transfected with control vector or non-transfected cells. Treatment with pSecTag2B-vaso twice weekly for 4 weeks resulted in the inhibition of tumor growth and the prolongation of the survival of tumor-bearing mice. The sustained high level of vasostatin protein in serum could be identified in ELISA. Angiogenesis was apparently inhibited in tumor by immunohistochemical analysis. Angiogenesis was also inhibited in the chicken embryo CAM assay and mouse corneal micropocket assay. The increased apoptotic cells were found within the tumor tissues from the mice treated with plasmid DNA encoding vasostatin. Taken together, the data in the present study indicate that the cancer gene therapy by the intramuscular delivery of plasmid DNA encoding vasostatin, is effective in the inhibition of the systemic angiogenesis and tumor growth in murine models. The present findings also provide further evidence of the anti-tumor effects of the vasostatin, and may be of importance for the further exploration of the application of this molecule in the treatment of cancer.

AB - The growth and persistence of solid tumors and their metastasis are angiogenesis-dependent. Vasostatin, the N-terminal domain of calreticulin inclusive of amino acids 1-180, is a potent angiogenesis inhibitor. To investigate whether intramuscular administration of vasostatin gene has the anti-tumor activity in mouse tumor models, we constructed a plasmid DNA encoding vasostatin and a control vector. Production and secretion of vasostatin protein by COS cells transfected with the plasmid DNA encoding vasostatin (pSecTag2B-vaso) were confirmed by Western blot analysis and ELISA. Conditioned medium from vasostatin-transfected COS cells apparently inhibited human umbilical vein endothelial cell (HUVEC) and mouse endothelial cell (SVEC4-10) proliferation, compared with conditioned medium from the COS cells transfected with control vector or non-transfected cells. Treatment with pSecTag2B-vaso twice weekly for 4 weeks resulted in the inhibition of tumor growth and the prolongation of the survival of tumor-bearing mice. The sustained high level of vasostatin protein in serum could be identified in ELISA. Angiogenesis was apparently inhibited in tumor by immunohistochemical analysis. Angiogenesis was also inhibited in the chicken embryo CAM assay and mouse corneal micropocket assay. The increased apoptotic cells were found within the tumor tissues from the mice treated with plasmid DNA encoding vasostatin. Taken together, the data in the present study indicate that the cancer gene therapy by the intramuscular delivery of plasmid DNA encoding vasostatin, is effective in the inhibition of the systemic angiogenesis and tumor growth in murine models. The present findings also provide further evidence of the anti-tumor effects of the vasostatin, and may be of importance for the further exploration of the application of this molecule in the treatment of cancer.

KW - Angiogenesis

KW - Dna plasmid

KW - Gene therapy

KW - Vasostatin

UR - http://www.scopus.com/inward/record.url?scp=0036739437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036739437&partnerID=8YFLogxK

U2 - 10.1038/sj.gt.3301788

DO - 10.1038/sj.gt.3301788

M3 - Article

C2 - 12215887

AN - SCOPUS:0036739437

VL - 9

SP - 1207

EP - 1213

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 18

ER -